- Axiom plans Hong Kong IPO, hoping to carve new path for US biotechsAxiom Biosciences is thinking outside of the box, betting on a public debut in Hong Kong to raise capital and grow into a global company.BioSpace · 7d ago↗ source
- Tempus to acquire cancer test maker Personalis for $1.5BTempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.BioPharma Dive · 8d ago↗ source
- Tempus to buy cancer test-maker Personalis for $1.5BTempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.BioPharma Dive · 8d ago↗ source